SynthesisBMC anesthesiology2025
Granisetron for prevention of postoperative shivering in surgical patients: a systematic review and meta-analysis.
Synthesis in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background5-HT3 receptor antagonists, including granisetron, have demonstrated antiemetic effects and the ability to prevent perioperative shivering. We conducted a systematic review of randomized clinical trials to investigate granisetron’s preventive effects on shivering in surgical patients undergoing general or neuraxial anesthesia.
methodsWe searched PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials from inception to January 7, 2025, without language restrictions, and simultaneously searched study protocols in four registries. Randomized controlled trials comparing granisetron versus placebo in surgical patients were included. We excluded studies in which patients underwent surgeries with cardiopulmonary bypass or in which patients were not expected to be extubated after surgery. The primary outcome was the incidence of shivering, calculated as a risk ratio with 95% CI using a random-effects model. A trial sequential analysis (TSA) of the primary outcome was performed to reduce type 1 errors from repeated meta-analyses, calculating the required information size. The risk of bias was assessed using the Revised Cochrane risk of bias 2 tool.
resultsTwenty-four trials, totaling 2,165 patients (1,166 and 999 patients in the granisetron and control groups, respectively), were included. Our meta-analysis showed a significantly lower incidence of shivering in surgical patients who received granisetron (risk ratio, 0.34; 95% CI, 0.28–0.41; I2 = 9%). The Grading of Recommendation Assessment, Development, and Evaluation assessment for granisetron’s effect on shivering prevention was moderate. When only low risk-of-bias trials were included, the Z-cumulative curve crossed the TSA boundary of benefit, confirming a significant reduction in shivering incidence in the granisetron group. The optimal granisetron dose, however, remains unclear in this meta-analysis.
conclusionOur meta-analysis and TSA demonstrated that granisetron administration significantly reduced the incidence of shivering in patients undergoing surgery. While evidence regarding the general effect of granisetron on shivering is extensive, future studies should focus on determining the optimal dosage.
trial registrationThis meta-analysis is registered on PROSPERO(CRD42024616645).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.